Drug Trial Radar · NCT05757869
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20,284
Actual
Start
Apr 11, 2023
Primary completion
Dec 8, 2026
Study completion Dec 8, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Mar 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Conditions
- Atrial Fibrillation
Interventions
MilvexianDrug
Milvexian will be administered orally.
ApixabanDrug
Apixaban will be administered orally.
PlaceboDrug
Milvexian matching milvexian placebo will be administered orally.
Apixaban PlaceboDrug
Apixaban matching apixaban placebo will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the First Occurrence of Composite Endpoint of Stroke and Non-central nervous system (CNS) Systemic EmbolismTime frame: Up to 4 years
Locations
1,052 sites in 39 countries. Site status is shown where the registry gives one.
Advanced Cardiovascular, LLC
Alexander City, Alabama
Ascension St. Vincent's Health System
Birmingham, Alabama
SEC Clinical Research
Dothan, Alabama
HH Heart Center and Heart Center
Huntsville, Alabama
CB Flock Research Corporation
Mobile, Alabama
Mercy Gilbert Medical Center
Gilbert, Arizona
Valleywise Health Medical Center
Phoenix, Arizona
Arizona Arrhythmia Research Center
Phoenix, Arizona
Arizona Heart Hospital
Phoenix, Arizona
HonorHealth Neurology 1
Scottsdale, Arizona
HonorHealth Neurology
Scottsdale, Arizona
Arkansas Heart Hospital
Little Rock, Arkansas
Bakersfield Memorial Hospital
Bakersfield, California
Vitality Clinical Research
Beverly Hills, California
Chula Vista Cardiac Clinic
Chula Vista, California
Sharp Chula Vista Medical Center
Chula Vista, California
Mission Cardiovascular Research Institute
Fremont, California
Paradise Clinical Research Group LLC
Glendora, California
Miller Children's at Long Beach Medical Center
Long Beach, California
Los Angeles Cardiology Associates
Los Angeles, California
University of Southern California
Los Angeles, California
Merced Vein and Vascular Center
Merced, California
Radin Cardiovascular Medical Group
Newport Beach, California
California Medical Research Associates, Inc.
Northridge, California
Valley Clinical Trials, Inc.
Northridge, California
Desert Oasis Health Care
Palm Springs, California
Havana Research Institute LLC
Pasadena, California
Eisenhower Desert Cardiology Center
Rancho Mirage, California
Stanford Health Care
Redwood City, California
San Diego Cardiac Center
San Diego, California
Syrentis Clinical Research
Santa Ana, California
Ramin Manshadi, MD
Stockton, California
UCLA School of Medicine
Torrance, California
Cardiology Associates Medical Group
Ventura, California
North County Internal Medicine
Vista, California
John Muir Physician Network Clin. Research Center
Walnut Creek, California
Aurora Denver Cardiology Associates
Aurora, Colorado
Aurora Denver Cardiology Associates 1
Denver, Colorado
Paradigm Clinical Research Centers, Inc.
Wheat Ridge, Colorado
Bridgeport Hospital
Bridgeport, Connecticut
Showing 40 of 1,052 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.